rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precur-

controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20: 2486-94. 12. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Onceweekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003, in press. 13. Pangalis GA, Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP, Dimopoulou MN, Kyrtsonis MC, et al. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica 2002;87:500-6. 14. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:120921. 15. Barosi G, Marchetti M. The clinical utility of epoetin in cancer patients: a matter of perspective. Haematologica 2000;85: 449-50. 16. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, MartinDupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469-75. 17. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346:1584-6. 18. Johnson & Johnson. Summary of PRCA case reports. Available from URL: http://www.jnj.com/news/jnj_news/ 1021024_095632.htm 19. Eckardt KU, Casadevall N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865-9. 20. Kruger A, Schroer W, Rohrs F, Vescio G. PRCA in a patient treated with epoetin beta. Nephrol Dial Transplant 2003; 18: 1033-4. 21. Cavill I, Williams JD. Benefits of recombinant human erythropoietin. Lancet 2002;360:1606-7. 22. Giraudier S, Quint L, Nataf J, Mayeux P, Casadevall N. Epoantibodies induced arythroblastopenia in MDS: two cases with eitherr alfa or beta recombinant erythropoietin. Leuk Res 2003;27 Suppl 1:S99[abstract]. 23. Alessandrino EP, Amadori S, Cazzola M, Locatelli F, Mecucci C, Morra E, et al. Myelodysplastic syndromes: recent advances. Haematologica 2001; 86:1124-57. 24. Rigolin GM, Porta MD, Bigoni R, Cavazzini F, Ciccone M, Bardi A, et al. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on MayGrunwald-Giemsa-stained bone marrow samples. Br J Haematol 2002;119:652-9. 25. Cazzola M. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. Int J Hematol 2000;72:134-8. 26. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46. 27 Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 2002; 68: 180-5. 28. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, et al. Evidenceand consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87:1286-306. 29. Cazzola M. Practice guidelines for the therapy of primary myelodysplastic syndromes: a word of caution about their translation into clinical practice. Haematologica 2002;87: 1240-1. 30. Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, et al. A novel method utilizing markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000;85:564-72. 31. Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 2000;85:561-3. 32. Parisotto R, Wu M, Ashenden MJ, Emslie KR, Gore CJ, Howe C, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001;86:128-37. 33. Ashenden MJ. A strategy to deter blood doping in sport. Haematologica 2002;87:225-32. 34. Nelson M, Ashenden M, Langshaw M, Popp H. Detection of homologous blood transfusion by flow cytometry: a deterrent against blood doping. Haematologica 2002;87:881-2. 35. Cazzola M. Further concerns about the medical risks of blood doping. Haematologica 2002;87:232. 36. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80. 37. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6. 38. Baron F, Frere P, Beguin Y. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engrafment. Haematologica 2003;88:718-20.